EUROPEAN PATENT, NOTICE OF ALLOWANCE

Today DiaGenic received notice of allowance for its European family 2 patent application, 0377005.4. The claims allowed cover the use of number of important gene sequences in blood for diagnosis and monitoring of, among others, breast cancer and Alzheimer’s disease. The patent when granted will be valid until 2023. MD PhD Erik Christensen, managing director of DiaGenic comments, “The new European patent is an important milestone which strengthens our position in Europe. The company will now have a broad patent protection in the 27 European countries for both Alzheimer’s disease and Breast cancer. The company’s recently CE marked diagnostic tests for these diseases; ADtect® and BCtect®, have thus strong protection also in Europe”. Contact: MD PhD Erik Christensen, Managing Director Telephone: +47 95939918 e-mail: erik.christensen@diagenic.com